Eskil has several years of experience of pharmaceutical development of small molecules and biologics. He has a strong scientific background with a PhD in Medical microbiology from Lund University followed by post doc sessions at University of Cambridge and Lund University working within immunology and vaccine development, respectively. He has worked at small as well as large pharma organizations (ACADIA Pharmaceuticals and AstraZeneca). Eskil has particular interest and expertise in pharmacokinetics (PK) and has worked as DMPK project leader at AstraZeneca. In that role, he represented the DMPK organization in drug projects from lead optimization up to Ph2b, a role in the boundary between the discovery and the clinical organization. The role encompassed accountability for the delivery of the ADME, PK and PK/PD parts for candidate selection. Over the years, Eskil has gained experience from working with respiratory disease in e.g. asthma, COPD, and cystic fibrosis, but also autoimmune indications. Eskil joined Truly Labs in 2017 as Principal Scientist and Consultant and will strengthen the capability in preclinical and clinical pharmacokinetics as well as in quantitative pharmacology (PK/PD) and ADME.